Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ASCEND Data Puts InterMune’s Pirfenidone On Top

This article was originally published in The Pink Sheet Daily

Executive Summary

Phase III trial of idiopathic pulmonary fibrosis drug puts company in strong position for FDA approval of first treatment for orphan disease and strong reimbursement in U.S. and abroad.

You may also be interested in...



Deal Watch: Roche Wins Potential Blockbuster Esbriet In $8.3B Buyout Of InterMune

While Valeant prepares for an October court date to resolve Allergan’s attempt to fend off its latest takeover attempt, the acquisitive Canadian specialty firm picked up some dermatology products from Valeo Pharma. Also this week, Cilag acquired Covagen and Vaccinogen raised $80 million for development of OncoVAX.

Roche Wins InterMune, But For A Price

With the $8.3 billion purchase price, Roche gains InterMune’s sole drug, pirfenidone for idiopathic pulmonary fibrosis, pending at FDA with action expected Nov. 23.

Two Treatments For IPF Edge Closer To Market, Will Come Down To Subtle Differences

InterMune’s pirfenidone and Boehringer Ingelheim’s nintedanib are neck-and-neck in the race to be the first drug interventions in the U.S. for the fatal lung disease. Phase III data from both drugs were presented at the American Thoracic Society meeting and published in the NEJM May 18.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS076871

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel